1531 / 2894
16. Koch CG, Li L, Sessler DI, et al: Duration of red-cell
storage and complications after cardiac surgery.
N Engl J Med 358:1229-1239, 2008.
17. Adamson JW: New blood, old blood, or no blood?
N Engl J Med 358:1295-1296, 2008.
18. Weiskopf RB, Viele MK, Feiner J, et al: Human
cardiovascular and metabolic responses to acute,
severe isovolemic anemia. JAMA 279:217, 1998.
19. Shorr AF, Duh MS, Kelly KM: Red blood cell trans-
fusion and ventilator-associated pneumonia. A
potential link? Crit Care Med 32:666-674, 2004.
20. Taylor RW, O’Brien J, Trottier SJ: Red blood cell
transfusions and nosocomial infections in critically
ill patients. Crit Care Med 34:2302-2308, 2006.
21. Ely EW, Bernard GR: Transfusions in critically ill
patients. N Engl J Med 340:467, 1999.
22. Walsh TS, McClelland DBL: When should we trans-
fuse critically ill and perioperative patients with
known coronary artery disease? Br J Anaesth
90:709, 2003.
23. McCrossan L, Masterson G: Blood transfusion in
critical illness. Br J Anaesth 88:6, 2002.
24. Hebert PC, Fergusson DA: Red blood cell transfu-
sions in critically ill patients. JAMA 288:1525,
2002.
25. Vincent JL, Baron JF, Reinhart K, et al: Anemia and
blood transfusion in critically ill patients. JAMA
288:1499, 2002.
26. Vincent JL, Sakr Y, Sprung C, et al: Are blood trans-
fusions associated with greater mortality rates?
Anesthesiology 108:31-39, 2008.
27. Nuttall GA, Houle TT: Liars, damn liars and pro-
pensity scores. Anesthesiology 108:3-4, 2008.
28. Saxena S, Wehrli G, Makarewicz K, et al: Monitoring
for underutilization of RBC components and plate-
lets. Transfusion 41:587, 2001.
29. Weiskopf RB: Do we know when to transfuse red
cells to treat acute anemia? Transfusion 38:517,
1998.
30. Popovsky MA, Whitaker B, Arnold NL: Severe
outcomes of allogeneic and autologous blood dona-
tions: Frequency and characterization. Transfusion
35:734, 1995.
31. Goldman M, Remy-Prince S, Trepanier A: Autolo-
gous donation error rates in Canada. Transfusion
37:523-527, 1997.
32. Miller RD, Von Ehrenberg W: Should the same
indication be used for both autologous and homo-
logous transfusions? Transfusion 35:703, 1995.
33. American Society of Anesthesiologists: Transfusion
Practices: Questions and Answers, 3rd ed. Chicago,
American Society of Anesthesiologists, 1998, pp 8-9.
34. Boyd PR, Sheedy KC, Henry JB: Type and screen:
Use and effectiveness in elective surgery. Am J Clin
Pathol 74:694, 1980.
35. Oberman AJ, Barnes BA, Friedman BA: The risk of
abbreviating the major crossmatch in urgent or
massive transfusion. Transfusion 18:137, 1978.
36. Sarma DP: Use of blood in elective surgery. JAMA
243:1536, 1980.
37. Friedman BA: An analysis of surgical blood use in
United States hospitals with application to the
maximum surgical blood order schedule. Transfu-
sion 19:268, 1979.
38. Walker RH: What is a clinically significant anti-
body? In Polesky HF, Walker RH (eds): Safety and
Transfusion Practices. Skokie, IL, College of Ameri-
can Pathologists, 1982, p 79.
39. Gervin AS, Fischer RP: Resuscitation of trauma
patients with type-specific uncrossmatched blood.
J Trauma 24:327, 1984.
40. Moore GL, Peck CC, Sohmer PR, et al: Some pro-
perties of blood stored in CPDA-1 solution. Trans-
fusion 21:135, 1981.
41. Valeri CR: Measurement of viable ADSOL-preser-
ved human red cells. N Engl J Med 312:377, 1985.
42. Vovric VA, Archer GT, Wisdom L, et al: Thirty-five-
day modified red cells and 7-day stored platelet
concentrates from triple bags of identical PVC
formation. Vox Sang 49:181, 1985.
43. Nishiyama T, Hayashi D: Electrostatic field can
preserve red blood cells in stored blood prepara-
tions. J Anesth 21:42-46, 2007.
44. Brohi K, Cohen MJ, Ganter MT, et al: Acute trau-
matic coagulopathy: Initiated by hypoperfusion.
Ann Surg 245:812-818, 2007.
45. Miller RD, Robbins TO, Tong MJ, et al: Coagulation
defects associated with massive blood transfusions.
Ann Surg 174:794, 1971.
46. Counts RB, Haisch C, Simon TL, et al: Hemostasis
in massively transfused trauma patients. Ann Surg
190:91, 1979.
47. Reed RL, Heimback DM, Counts RB, et al: Pro-
phylactic platelet administration during massive
transfusion. Ann Surg 203:40, 1986.
48. Miller RD: Complications of massive blood trans-
fusions. Anesthesiology 39:82, 1973.
49. NIH Consensus Conference: Fresh frozen plasma:
Indications and risks. JAMA 253:551, 1985.
50. Levi M, ten Cate H, van der Poll T, van Deventer JH:
Pathogenesis of disseminated intravascular coagu-
lation. JAMA 270:975, 1993.
51. Lavee J, Martinowitz U, Mohr R, et al: The effect of
transfusion of fresh whole blood versus platelet
concentrates after cardiac operations. J Thorac
Cardiovasc Surg 97:204, 1989.
52. Erber WN, Tan J, Grey D, et al: Use of unrefrigerated
fresh whole blood in massive transfusion. Med J
Aust 165:11, 1996.
53. Harvey MP, Dwyer P, Dean MG: Fighting a rear-
guard action in the massively transfused patient.
Med J Anest 165:9, 1996.
54. Murray DJ, Olson J, Strauss R, Tinker JH: Coagula-
tion changes during packed red cell replacement of
major blood loss. Anesthesiology 69:839, 1988.
55. Kang Y, Lewis JH, Navalgung A, et al: Epsilon-ami-
nocaproic acid for treatment of fibrinolysis during
liver transplantation. Anesthesiology 66:766, 1987.
56. Weiskoph RB: Recombinant-activated coagulation
factor VIIa (NOVOSEVEN®): Current development.
Vox Sang 92:281-288, 2007.
57. Mannucci PM, Levi M: Prevention and treatment of
major blood loss. N Engl J Med 356:2301-2311, 2007.
58. Laupacis A, Fergusson D,for the International
Study of Perioperative Transfusion Investigators:
Drugs to minimize perioperative blood loss in
cardiac surgery: Meta-analyses using perioperative
blood transfusion as the outcome. Anesth Analg
85:1258, 1997.
59. Leslie SD, Toy PT: Laboratory hemostatic abnorma-
lities in massively transfused patients given red
blood cells and crystalloid. Am J Clin Pathol 96:770,
1991.
60. Parshuram CS, Jaffe AR: Prospective study of potas-
sium-associated acute transfusion events in pediatric
intensive care. Pediatr Crit Care Med 4:65-68, 2003.
61. Linko K, Tigerstedt I: Hyperpotassemia during
massive blood transfusions. Acta Anaesthesiol
Scand 28:220, 1984.
62. Collins JA, Simmons RL, James PM, et al: The acid-
base status of seriously wounded combat casualties.
I. Resuscitation with stored blood. Ann Surg 173:6,
1971.
63. Miller RD, Tong MJ, Robbins TO: Effects of massive
transfusion of blood on acid-base balance. JAMA
216:1762, 1971.
64. Holness L: Total fatalities (FDA). ABC Newsletter,
April 13, 2007.
65. Capon SM, Sacher RA: Hemolytic transfusion reac-
tions: A review of mechanisms, sequelae, and mana-
gement. J Intensive Care Med 4:100, 1989.
66. Linden JV, Wagner K, Voytovich AE, Sheehan J:
Transfusion errors in New York State: An analysis
of 10 years’ experience. Transfusion 40:1207-1213,
2000.
67. Linden JV, Tourault MA, Schribner CL: Decrease in
frequency of transfusion fatalities. Transfusion
37:243, 1997.
68. Seyfried H, Walewska I: Immune hemolytic trans-
fusion reactions. World J Surg 11:25, 1987.
69. Lopas H: Immune hemolytic transfusion reactions
in monkeys: Activation of the kallikrein system. Am
J Physiol 225:372, 1973.
70. Seager OA, Nesmith MA, Begelman KA, et al:
Massive acute hemodilution for incompatible blood
reaction. JAMA 229:788, 1974.
71. Schonewille H, van de Watering LMG, Brand A:
Additional red blood cell alloantibodies after blood
transfusions in nonhematologic alloimmunized
patient cohort: Is it time to take precautionary
measures? Transfusion 46:630, 2006.
72. King KE, Shirey S, Thoman SK, et al: Universal
leukoreduction decreases the incidence of febrile
nonhemolytic transfusion reactions to RBCs. Trans-
fusion 44:25-29, 2004.
73. Oberman HA: Controversies in transfusion medi-
cine: Should a febrile transfusion response occasion
the return of the blood component to the blood
bank? Con Transfusion 34:353, 1994.
74. Widman FK: Controversies in transfusion medi-
cine: Should a febrile transfusion response occasion
the return of the blood component to the blood
bank? Pro Transfusion 34:356, 1994.
75. Sandler SG, Mallory D, Malamut D, Eckrich R: IgA
anaphylactic transfusion reactions. Transf Med Rev
9:1-8, 1995.
76. Kleinman S, Chan P, Robillard P: Risks associated
with transfusion of cellular blood components in
Canada. Transf Med Rev 17:120-162, 2003.
77. Fiebig EW, Busch MP: Infectious risks of transfu-
sion. In Spiess BD, et al (ed): Perioperative Trans-
fusion Medicine, 2nd ed. Philadelphia, Lippincott
William & Wilkins, 2006, pp 131-152.
78. Blachman MA, Vamvankas EC: The continuing risk
of transfusion-transmitted infections. N Engl J Med
355:1303-1305, 2006.
79. Kleinman SH, Busch MP: Assessing the impact of
HBV NAT on window period reduction and resi-
dual risk. J Clin Virol 36:S23-S29, 2006.
80. Hladik W, Dollard SC, Mermin J: Transmission of
human herpesvirus 8 by blood transfusion. N Engl
J Med 355:1331-1338, 2006.
81. Busch MP, Caglioti S, Robertson EF: Screening the
blood supply for West Nile virus RNA by nucleic
acid amplification testing. N Engl J Med 353:
460-467, 2005.
82. Tong MJ, El-Farra NS, Reikes AR, et al: Clinical
outcomes after transfusion-associated hepatitis C.
N Engl J Med 332:1463, 1995.
83. Cohen ND, Muñoz A, Reitz BA, et al: Transmission
of retroviruses by transfusion of screened blood in
patients undergoing cardiac surgery. N Engl J Med
320:1173, 1989.
84. Preiksaitis VK, Grumet FC, Smith WK, et al: Trans-
fusion-acquired cytomegalovirus infection in
cardiac surgery patients. J Med Virol 15:283, 1985.
85. Preiksaitis JK, Brown L, McKenzie M: The risk of
cytomegalovirus infection in seronegative transfu-
sion recipients not receiving exogenous immunode-
pression. J Infect Dis 157:523, 1988.
86. Wilhelm JA, Matter L, Schopfer K: The risk of trans-
mitting cytomegalovirus to patients receiving blood
transfusions. J Infect Dis 154:169, 1986.
87. Tripple MA, Bland JJ, Murphy MJ, et al: Sepsis asso-
ciated with transfusion of red cells contaminated
with
Yersinia enterocolitica
. Transfusion 30:207,
1990.
88. Glynn SA, Busch MP, Schreiber GB, et al: Effect of
a national disaster on blood supply and safety.
JAMA 289:2246, 2003.
89. Ohto H, Anderson KC: A survey of transfusion-
associated graft-versus-host disease in immuncom-
petent recipients. Trans Med Rev 10:31-43, 1996.
90. Hayashi H, Nishiuchi T, Tamura H, et al: Transfu-
sion-associated graft-versus-host disease caused by
leukocyte-filtered stored blood. Anesthesiology
79:1419, 1992.
91. Toy P, Popovsky MA, AbrahamE, et al: Transfusion-
related acute lung injury: definition and review. Crit
Care Med 33:721-726, 2005.
92. Zhou L, Giacherio D, Cooling L, Davenport RD: Use
of B-natriuretic peptide as a diagnostic marker in
the differential diagnosis of transfusion-associated
circulatory overload. Transfusion 45:1056-1063,
2005.
93. Kleinman S, Caulfield T, Chan P, et al: Toward an
understanding of transfusion-related acute lung
injury: statement of a consensus panel. Transfusion
44:774-789, 2004.
Terapia transfusional
1531
45
Sección III
Control de la anestesia
© ELSEVIER. Fotocopiar sin autorización es un delito